Aperio Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-44,524
Closed -$2.34M 2476
2020
Q3
$2.34M Buy
44,524
+4,730
+12% +$196K 0.01% 1045
2020
Q2
$1.32M Buy
39,794
+3,478
+10% +$111K ﹤0.01% 1288
2020
Q1
$988K Buy
36,316
+7,459
+26% +$208K ﹤0.01% 1316
2019
Q4
$569K Buy
28,857
+389
+1% +$6.22K ﹤0.01% 1731
2019
Q3
$369K Buy
28,468
+5,100
+22% +$61.6K ﹤0.01% 1920
2019
Q2
$291K Sell
23,368
-434
-2% -$5.76K ﹤0.01% 2037
2019
Q1
$346K Buy
23,802
+1,354
+6% +$17.3K ﹤0.01% 1939
2018
Q4
$248K Sell
22,448
-836
-4% -$11.6K ﹤0.01% 2035
2018
Q3
$612K Buy
23,284
+1,913
+9% +$51.7K ﹤0.01% 1662
2018
Q2
$437K Buy
21,371
+3,102
+17% +$66.6K ﹤0.01% 1808
2018
Q1
$332K Buy
18,269
+1,202
+7% +$20K ﹤0.01% 1900
2017
Q4
$238K Sell
17,067
-773
-4% -$10.4K ﹤0.01% 2071
2017
Q3
$330K Sell
17,840
-311
-2% -$5.2K ﹤0.01% 1869
2017
Q2
$307K Buy
18,151
+1,562
+9% +$23.8K ﹤0.01% 1883
2017
Q1
$221K Sell
16,589
-667
-4% -$10.4K ﹤0.01% 1994
2016
Q4
$260K Buy
17,256
+865
+5% +$11.4K ﹤0.01% 1862
2016
Q3
$192K Buy
16,391
+2,224
+16% +$26.1K ﹤0.01% 1952
2016
Q2
$153K Buy
+14,167
New +$146K ﹤0.01% 1925
2016
Q1
Sell
-11,509
Closed -$171K 2079
2015
Q4
$171K Buy
11,509
+1,484
+15% +$24.8K ﹤0.01% 1854
2015
Q3
$165K Buy
10,025
+1,129
+13% +$23.1K ﹤0.01% 1791
2015
Q2
$203K Buy
+8,896
New +$177K ﹤0.01% 1860

Aperio Group's MNTA Position: Q4 2020 in Review

Aperio Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 44,524 shares — an estimated $2.34M sold.

Aperio Group first reported a position in MNTA in Q2 2015 and held it in 21 quarters. The position peaked at $2.34M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • Aperio Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Aperio Group sold 44,524 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $2.34M.
  • Aperio Group first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2015 and held it in 21 quarters.
  • Aperio Group's Momenta Pharmaceuticals, Inc. position peaked at $2.34M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.